[1] Lu X Y, Xi T, Lau W Y,et al. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J]. Ann Surg Oncol, 2011,18(8):2210-2217.
[2] 黄杰灵,李远章,李亮杰,等. Gd-EOB-DTPA 增强 MRI 在乙肝肝硬化背景下肝癌的诊断价值[J]. CT 理论与应用研究,2019,28(4): 485-492.
[3] Huang K, He Y, Liang T,et al. Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma[J]. Sci Rep, 2024,14(1):3314.
[4] Zhang J, Qi Y P, Ma N,et al. Overexpression of epcam and CD133 correlates with poor prognosis in dual-phenotype hepatocellular carcinoma[J]. J Cancer, 2020,11(11):3400-3406.
[5] 吴茜,郁义星,范艳芬,等. 增强MRI列线图模型在预测双表型肝细胞癌中的应用价值[J].中华医学杂志,2022,102(15):1086-1092.
[6] 郑巧灵,冯昌银,连渊娥,等.双表型肝细胞癌6例临床病理学分析[J].中华病理学杂志,2020,49(12): 1320-1322.
[7] 金震滨,徐磊,张学琴,等.钆塞酸二钠增强MRI列线图术前预测双表型肝细胞癌及根治切除术后复发的价值[J].放射学实践,2024,39(11):1488-1493.
[8] Ouyang X, Yan Y, Zhang S,et al. Microvascular invasion is associated with poor survival in patients with dual-phenotype hepatocellular carcinoma[J]. Am J Clin Pathol,2024,161(3):245-255.
[9] Gu H X, Huang X S, Xu J X,et al. Diagnostic value of MRI features in dual-phenotype hepatocellular carcinoma: a preliminary study[J]. J Digit Imaging,2023,36(6):2554-2566.
[10] 张宁,周怡然,于长江,等.钆赛酸二钠增强MRI术前评估GPC3和CK19阳性双表型肝细胞癌的价值[J].中华放射学杂志,2024,58(4):444-447.
[11] Liu M T, Zhang J Y, Xu L,et al. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS 2018 and other imaging features for preoperative prediction of dual phenotype hepatocellular carcinoma[J]. Radiol Med, 2023 ,128(11):1333-1346.
[12] 瞿晓春,李勇.CT对肝局灶性慢性炎症病变与肝内肿块型胆管细胞癌的鉴别诊断[J].中国医学影像学杂志,2023,31(5):504-508,516.
[13] 李伟,曹丽君,吴斌,等.术前磁共振成像对肝癌患者射频术后复发的预测价值[J].武警医学,2024,35(7):613-616.
[14] 葛健康,王尧,王雷,等.影像学表现为肝内胆管细胞癌的双表型肝细胞癌1例报告[J].临床肝胆病杂志,2020,36(4):883-884.